Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 17, 2026
TickeronGET DAILY SIGNALS
Standard BioTools (LAB) Reports Q3 2026 Earnings: Revenue Edges Down 1% but Beats Estimates

Standard BioTools (LAB) Reports Q3 2026 Earnings: Revenue Edges Down 1% but Beats Estimates

Key Takeaways

  • Standard BioTools reported third quarter 2026 revenue of $19.39 million, down about 1% year over year but above the consensus estimate of roughly $18.80 million.
  • GAAP net income reached $13.48 million, a sharp swing from a $34.69 million net loss a year earlier, driven largely by a $30.0 million Illumina-related gain.
  • Net loss from continuing operations narrowed to $15.0 million from $31.7 million, while diluted EPS came in at $0.03 versus a consensus of -$0.02.
  • Gross margin improved to 55.9% from 48.5% a year ago, while operating expenses fell 28% to $30.6 million.
  • Instruments revenue rose 18%, but consumables declined 4% and services and other revenue fell 12%.
  • For deeper context, review the ticker's Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
  • Explore Trending AI Robots to see AI-driven trading strategies currently in focus.

Earnings Context and Strategic Background

Standard BioTools continues its multi-year shift from a specialized life-science instruments provider toward a broader consolidator role in the tools space. The third quarter of 2026 unfolded during a critical period, with the company preparing to finalize an all-stock merger with Treeline Biosciences and planning the sale of its legacy mass cytometry and microfluidics operations. Against this backdrop, the focus remains on whether the core business can stabilize revenue and improve margins as management repositions the portfolio. The substantial cash position from the Illumina and SomaLogic transactions also positions the company for additional moves, so each earnings release offers insight into both near-term performance and the longer-term strategy.

Q3 Results Breakdown

For the quarter ended September 30, 2026, Standard BioTools posted total revenue of $19.39 million, a modest decline from $19.55 million in the prior-year period yet ahead of the roughly $18.80 million consensus. Product revenue climbed 4% to $14.3 million, supported by an 18% increase in instruments to $6.0 million; consumables eased 4% to $8.3 million, and services and other revenue dropped 12% to $5.1 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Gross margin expanded to 55.9% from 48.5%, helped by a better product mix and reduced warranty expenses. Operating expenses declined 28% to $30.6 million, which contributed to narrowing the net loss from continuing operations to $15.0 million from $31.7 million. A $30.0 million gain related to the termination of Illumina earnout and royalty agreements lifted GAAP net income to $13.48 million, or $0.03 per diluted share, versus a $34.69 million net loss last year.

Market Reaction and Investor Sentiment

The quarter came across as a modest operational positive. Revenue exceeded expectations, gross margin expanded meaningfully, and the GAAP profit—though one-time in nature—highlighted the financial benefits of the Illumina-related divestiture. Sentiment, however, continues to center on the pending Treeline merger and the planned exits from the mass cytometry and microfluidics businesses, which will reshape the company’s scale and focus. Given the sizable non-recurring items, investors appear to be weighing the strategic milestones more heavily than the slight year-over-year revenue decline.

What to Watch Going Forward

The key variable ahead is how cleanly the restructuring roadmap is executed. The all-stock Treeline merger is slated to close in the fourth quarter of 2026, and the divestitures are meant to streamline operations and free up resources. Monitoring the timing, terms, and any associated costs or adjustments will be essential.

On the operating side, sustainability of the gross margin improvement, the balance between instrument placements and recurring revenue streams, and ongoing expense discipline deserve attention. Full-year 2026 revenue guidance of $80 million to $85 million offers a useful benchmark for the remaining businesses during the transition. The enlarged cash and investments balance, bolstered by SomaLogic proceeds, will also stay in focus as management decides how to allocate it toward future deals or integration.

Enhancing Research with Tickeron’s AI Tools

In my own work, I find Tickeron’s AI Screener helpful for quickly filtering stocks by technical patterns, fundamentals, and industry benchmarks. It lets me scan thousands of names with customizable criteria and surface ideas that might otherwise take longer to identify manually. For names like Standard BioTools, adding this layer has become a regular part of reviewing quarterly updates and peer comparisons.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LAB

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


LAB in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 17, 2026

LAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 41 cases where LAB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

Following a +10.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where LAB advanced for three days, in 202 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 49 cases where LAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

The Momentum Indicator moved below the 0 level on November 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LAB as a result. In 80 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.

The Moving Average Convergence Divergence Histogram (MACD) for LAB turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 50 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

LAB moved below its 50-day moving average on November 16, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

The Aroon Indicator for LAB entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 50 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.462) is normal, around the industry mean (4.142). P/E Ratio (2.891) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.300) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. LAB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was -16%. POAS experienced the highest price growth at 158%, while LFWD experienced the biggest fall at -44%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -40%. For the same stocks of the Industry, the average monthly volume growth was 13% and the average quarterly volume growth was -20%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 63
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of integrated fluidic circuit systems

Industry MedicalNursingServices

Industry
Medical Specialties
Address
50 Milk Street
Phone
+1 650 266-6000
Employees
389
Web
https://www.standardbio.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
Cerebras Systems (CBRS) dropped -6.48% to $97.43 in regular trading from the prior close of $104.18, reversing an early premarket gain of roughly +3%. No verified news or fundamental catalyst found for the intraday reversal; the move is likely profit-taking after the stock's +21% post-earnings rebound, consistent with a name that averages a ±4.5% daily swing and remains 65% below its first-day close.